Effectiveness of Dexamethasone in Pediatric Pneumococcal Meningitis

出处
期刊:Aap Grand Rounds [American Academy of Pediatrics]
卷期号:54 (1): 3-3
标识
DOI:10.1542/gr.54-1-03
摘要

Source: Giolito A, Levy C, Varon E, et al. Adjunctive dexamethasone and 30- day all-cause death after hospital admission in paediatric pneumococcal meningitis: a propensity score analysis. Lancet Child Adolesc Health. 2025;9(4):255-261; doi: 10.1016/S2352-4642(25)00029-X.Investigators from multiple institutions in France conducted a retrospective study to assess the effect of dexamethasone in reducing 30-day, all-cause mortality in children with pneumococcal meningitis. For the study, they abstracted data from a French national surveillance system that includes data on patients with confirmed bacterial meningitis who received care at 1 of 238 sites in France. Demographic, clinical, and outcome data are included in the database. Study participants were children <18 years old with pneumococcal meningitis between 2005 and 2022. The diagnosis was confirmed by a positive cerebrospinal fluid (CSF) culture, antigen test, PCR, or a positive blood culture associated with CSF pleocytosis. Patients who did not receive a third-generation cephalosporin were excluded. Study participants were classified by whether they received dexamethasone 0.15 mg/kg every 6 hours for 4 days (per national guidelines) or no dexamethasone (control group). The primary outcome was all-cause, 30-day mortality. Secondary outcomes included hearing loss and neurologic complications (eg, seizures). Infection complications, such as intracerebral empyema, recurrent meningitis, and septic thrombosis were included as a safety outcome. Outcomes were compared between those in the dexamethasone and control groups using logistic regression. A propensity score-based analysis was used to account for multiple clinical and demographic characteristics.Data were analyzed on 1,231 study participants, including 581 who received dexamethasone and 650 controls. The median age of study participants was 1.1 years. There was a change in pneumococcal serotype associated with meningitis after the PCV13 vaccine was implemented in France in 2010. Prior to 2010, 60% of patients had PCV13 serotypes, and after that, 86% had non-PCV13 serotypes. Among the group of study children who received dexamethasone as an adjunct treatment, 36 (6%) died within 30 days; 69 (12%) of those in the control group died (adjusted odds ratio [aOR], 0.39; 95% confidence interval [CI], 0.23, 0.65). The use of dexamethasone was associated with a decreased risk of death among patients 1–5 years old (aOR, 0.30; 95% CI, 0.10, 0.88) and those >5 years of age (aOR, 0.14; 95% CI, 0.03, 0.64). The association was attenuated in infants <1 year old (aOR, 0.53; 95% CI, 0.28, 1.01). There were no significant differences between patients in the dexamethasone and control groups in rate of hearing loss (aOR, 1.08; 95% CI, 0.43, 2.73), neurologic complications (aOR, 1.13; 95% CI, 0.83, 1.53), or infectious complications (aOR, 0.79; 95% CI, 0.41, 1.53).The authors conclude that use of dexamethasone was associated with a decreased risk of death in children with pneumococcal meningitis.Dr Loyal has disclosed no financial relationship relevant to this commentary. This commentary does not contain a discussion of an unapproved/investigative use of a commercial product/device.S. pneumoniae strains not covered by vaccination remain a formidable threat to children.1 In the current study, French investigators demonstrate that dexamethasone administered to children with pneumococcal meningitis within 12 hours of initiation of antimicrobials lowered the risk of mortality. Strengths of the study include multiple sites participating in a national surveillance system, confirmed pneumococcal meningitis, and data spanning almost 18 years. In the absence of randomized controlled studies (RCTs), the investigators chose to perform a propensity score analysis, which allows for mitigating bias and mimicking an RCT using retrospective observational data.A propensity score acts as a surrogate for all the covariates used to estimate the probability of 1 study participant being assigned to the treatment group or control group based on the participant’s characteristics or pre-treatment conditions.2 In this study, the investigators created propensity scores by estimating the probability of receiving dexamethasone for each patient using baseline covariates (eg, demographics, clinical condition, laboratory results, disease management) and logistic regression. To balance the groups more fairly, each patient was given a 'stabilized weight,' which was based on the inverse of their probability of receiving dexamethasone. This created a 'pseudo-randomized' group for comparison and smooths out extreme values. The limitation with this type of analysis is the inability to control for unmeasured confounders.The investigators reference 2 studies in which the effectiveness of vancomycin was lowered in the presence of dexamethasone.3,4 In 1 study in rabbits with pneumococcal infection, levels of vancomycin in the CSF were lower in the group treated with dexamethasone.3 The second study was a case report of 2 patients with pneumococcal meningitis whose CSF still contained S. pneumoniae on days 6 and 10 of illness despite antimicrobial treatment.4 The authors surmised that dexamethasone administration may have affected penetration of antibiotics into the CSF.4 The lack of more robust data to elucidate the effects of dexamethasone on antimicrobial penetration in the CSF is problematic, especially in the context of the current study showing reduced mortality.The concomitant use of dexamethasone with antimicrobial therapy in children with pneumococcal meningitis appears to lower mortality.Despite the absence of long-term follow-up to assess hearing and neurologic sequelae, the results of the current study can inform future guidelines on the use of dexamethasone in the treatment of the leading cause of bacterial meningitis worldwide, S. pneumoniae.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
微笑的烨霖完成签到,获得积分10
刚刚
慕青的应助被369ninja采纳,获得10
1秒前
lllx完成签到,获得积分10
1秒前
1秒前
方苠发布了新的文献求助10
1秒前
彭晶晶完成签到 ,获得积分10
2秒前
整齐的羞花完成签到,获得积分10
2秒前
认真碧灵完成签到,获得积分10
3秒前
微晶纤维素完成签到,获得积分10
3秒前
3秒前
嚣张的小张完成签到,获得积分10
4秒前
4秒前
xl完成签到,获得积分10
5秒前
废柴养成计划完成签到,获得积分10
5秒前
壮观雁开完成签到,获得积分10
5秒前
5秒前
Sue发布了新的文献求助10
5秒前
7秒前
大方的冥茗完成签到 ,获得积分10
8秒前
我是一片云完成签到,获得积分10
8秒前
自然友灵完成签到,获得积分10
8秒前
roking完成签到,获得积分10
8秒前
小马甲的应助被闾丘翠桃采纳,获得10
9秒前
狐狸的贝完成签到,获得积分10
9秒前
9秒前
安详晓亦完成签到,获得积分10
9秒前
9秒前
牛牛完成签到,获得积分10
10秒前
10秒前
coff完成签到,获得积分10
12秒前
13秒前
研友_ZG4ml8发布了新的文献求助10
13秒前
学术的刘完成签到,获得积分10
13秒前
Allen完成签到,获得积分10
14秒前
牧芷珊完成签到,获得积分10
14秒前
阿柠完成签到,获得积分10
14秒前
研友_Zbb4mZ完成签到,获得积分10
14秒前
三七二一完成签到,获得积分10
14秒前
15秒前
JamesPei的应助被爱在西元前采纳,获得10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180146
求助须知:如何正确求助?哪些是违规求助? 9570319
关于积分的说明 21809739
捐赠科研通 7776294
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039